文献速递卫生政策与健康促进免疫规划

疫苗生产的复杂性与成本——概述

The complexity and cost of vaccine manufacturing - An overview.
PubMed 文献 · Vaccine · 2017-06-21

本文概述儿童疫苗获得并维持许可的流程与成本驱动因素,并说明以出口为目标时向低资源市场供应可负担疫苗的要求,包括世界卫生组织(WHO)预认证及支持性政策建议。文章指出,疫苗生产虽表面看似经济增长机会,但其复杂性和高固定成本限制潜在利润,且多数中低收入国家多年内需进口大部分设备、人员和耗材,进一步限制对本地经济的收益。

要点

  • 疫苗生产的技术与研发壁垒高、固定成本高,限制新生产商进入并导致现有生产商缩减与整合。
  • 以出口为目标需满足WHO预认证及支持性政策建议,才能以可负担价格供应低资源市场。
  • 多数中低收入国家多年内需进口大部分设备、人员和耗材,本地经济收益受限。

核心结论

  • 疫苗生产虽表面看似经济增长机会,但其复杂性和高固定成本限制潜在利润。
  • 对多数中低收入国家而言,大部分设备、人员和耗材多年内需进口,进一步限制对本地经济的收益。

研究设计与样本

  • 本文为概述性文章,描述儿童疫苗获得并维持许可的流程与成本驱动因素,并说明以出口为目标时向低资源市场供应可负担疫苗的要求。

主要发现

  • 领先跨国公司对复杂生产流程、高技术及研发进入壁垒和疫苗生产成本有良好理解。
  • 发展中国家的决策者、捐助方和投资者可能不了解持续限制新生产商数量并导致现有生产商缩减与整合的因素。
  • 文章指出疫苗生产的复杂性和高固定成本限制潜在利润。
  • 对多数中低收入国家而言,大部分设备、人员和耗材多年内需进口,进一步限制对本地经济的收益。

关键数值与推荐

  • 以出口为目标时,需满足向低资源市场以可负担价格供应疫苗的要求,包括世界卫生组织(WHO)预认证流程及支持性政策建议。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As companies, countries, and governments consider investments in vaccine production for routine immunization and outbreak response, understanding the complexity and cost drivers associated with vaccine production will help to inform business decisions. Leading multinational corporations have good understanding of the complex manufacturing processes, high technological and R&D barriers to entry, and the costs associated with vaccine production. However, decision makers in developing countries, donors and investors may not be aware of the factors that continue to limit the number of new manufacturers and have caused attrition and consolidation among existing manufacturers. This paper describes the processes and cost drivers in acquiring and maintaining licensure of childhood vaccines. In addition, when export is the goal, we describe the requirements to supply those vaccines at affordable prices to low-resource markets, including the process of World Health Organization (WHO) prequalification and supporting policy recommendation. By providing a generalized and consolidated view of these requirements we seek to build awareness in the global community of the benefits and costs associated with vaccine manufacturing and the challenges associated with maintaining consistent supply. We show that while vaccine manufacture may prima facie seem an economic growth opportunity, the complexity and high fixed costs of vaccine manufacturing limit potential profit. Further, for most lower and middle income countries a large majority of the equipment, personnel and consumables will need to be imported for years, further limiting benefits to the local economy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Plotkin S, Robinson JM, Cunningham G, et al. The complexity and cost of vaccine manufacturing - An overview. Vaccine. 2017. PMID: 28647170. doi:10.1016/j.vaccine.2017.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。